» Articles » PMID: 32466490

Severe Multiorgan Failure Following Yellow Fever Vaccination

Overview
Date 2020 May 30
PMID 32466490
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The yellow fever (YF) vaccination is recommended by the WHO for people traveling or living in endemic areas at risk for yellow fever infections in Africa and South America. Although the live attenuated yellow fever vaccine is a safe and efficient vaccine, rare serious adverse events after vaccination have been reported.

Case Presentation: We present the case of a 74-year-old male with multiorgan failure after yellow fever vaccination for a trip to Brazil. The patient required admission to the intensive care unit with a prolonged stay due to severe organ dysfunction. Five days after the YF vaccination, the patient experienced nausea, vomiting, diarrhea, and general illness. Three days later he sought medical attention and was transferred to the University Hospital Heidelberg with beginning multiorgan failure and severe septic shock, including hypotonia, tachypnea, thrombopenia, and acute renal failure the same day. Within one week after vaccination, antibodies against YF virus were already detectable and progressively increased over the next two weeks. Viral RNA was detected in serum on the day of admission, with a viral load of 1.0 × 10 copies/mL. The YF virus (YFV) RNA was also present in tracheal secretions for several weeks and could be detected in urine samples up to 20 weeks after vaccination, with a peak viral load of 1.3 × 10 copies/mL. After 20 weeks in the ICU with nine weeks of mechanical ventilation, the patient was transferred to another hospital for further recovery.

Conclusions: The risk for severe adverse events due to the YF vaccination should be balanced against the risk of acquiring a severe YF infection, especially in elderly travelers.

Citing Articles

Current Flavivirus Research Important for Vaccine Development.

Geerling E, Steffen T, Brien J, Pinto A Vaccines (Basel). 2020; 8(3).

PMID: 32867038 PMC: 7563144. DOI: 10.3390/vaccines8030477.


A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine.

Yan K, Vet L, Tang B, Hobson-Peters J, Rawle D, Le T Vaccines (Basel). 2020; 8(3).

PMID: 32660106 PMC: 7564786. DOI: 10.3390/vaccines8030368.

References
1.
Martin M, Weld L, Tsai T, Mootrey G, Chen R, Niu M . Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001; 7(6):945-951. PMC: 2631902. DOI: 10.3201/eid0706.010605. View

2.
Jonker E, Visser L, Roukens A . Advances and controversies in yellow fever vaccination. Ther Adv Vaccines. 2014; 1(4):144-52. PMC: 3991151. DOI: 10.1177/2051013613498954. View

3.
Campos W, Cenachi S, Soares M, Goncalves P, Vasconcelos-Santos D . Vogt-Koyanagi-Harada Disease following Yellow Fever Vaccination. Ocul Immunol Inflamm. 2019; 29(1):124-127. DOI: 10.1080/09273948.2019.1661498. View

4.
Cottin P, Niedrig M, Domingo C . Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines. 2013; 12(11):1351-68. DOI: 10.1586/14760584.2013.836320. View

5.
Slesak G, Gabriel M, Domingo C, Schafer J . [Severe Yellow fever vaccine-associated disease: a case report and current overview]. Dtsch Med Wochenschr. 2017; 142(16):1219-1222. DOI: 10.1055/s-0043-114729. View